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Abstract
Viruses use a limited set of host pathways for infection. These pathways represent bona fide antiviral targets with low
likelihood of viral resistance. We identified the salicylanilide niclosamide as a broad range antiviral agent targeting acidified
endosomes. Niclosamide is approved for human use against helminthic infections, and has anti-neoplastic and antiviral
effects. Its mode of action is unknown. Here, we show that niclosamide, which is a weak lipophilic acid inhibited infection
with pH-dependent human rhinoviruses (HRV) and influenza virus. Structure-activity studies showed that antiviral efficacy
and endolysosomal pH neutralization co-tracked, and acidification of the extracellular medium bypassed the virus entry
block. Niclosamide did not affect the vacuolar H+-ATPase, but neutralized coated vesicles or synthetic liposomes, indicating
a proton carrier mode-of-action independent of any protein target. This report demonstrates that physico-chemical
interference with host pathways has broad range antiviral effects, and provides a proof of concept for the development of
host-directed antivirals.
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Introduction
The discovery of antibiotics against microbes in the early 20th
century has had a major impact on society and saved countless
lives [1]. Yet, broad range inhibitors against viral pathogens are
presently not available. Classical antiviral strategies have targeted
viral structural or enzymatic motifs with high specificity and
potentially low side effects. These agents are, however, prone to
viral evasion, and select for resistant strains [2]. To identify novel
chemical inhibitors of virus infection we performed a high-content,
image-based infection screen using a library of approximately
1200 known bioactive and food and drug administration (FDA)
approved small compounds for their ability to inhibit human
rhinovirus (HRV) 16 infection of HeLa cells.
HRV belong to the genus Enteroviridae of the picornavirus family.
Picornaviruses are small, non-enveloped viruses with a capsid of
28–30 nm in diameter and a plus-sense, 6500–9000 nucleotide
RNA genome. The genome encodes a single poly-protein, which is
proteolytically processed during infection [3]. HRVs comprise
more than one hundred known serotypes. They are the most
frequent viral infections among humans and the predominant
cause of the common cold [4]. HRV infections can pose severe
health risks in patients with pre-existing airway conditions,
including chronic obstructive pulmonary disease, asthma or cystic
fibrosis. This may relate to the observation that HRVs are not
limited to the upper respiratory tract but also infect the lower
respiratory tracts [4]. Two receptor groups have been defined for
the species A and B viruses. The minor group viruses comprise
twelve members utilizing low-density lipoprotein receptor (LDLR)
proteins for cell entry, and the major group uses the intracellular
adhesion molecule 1 (ICAM1) [5]. These infections are typically
pH-dependent and require the passage of viruses through acidic
endosomal compartments. The recently discovered species C
HRVs, which are prevalent in young children appear to use
distinct but unknown attachment sites for infection [6].
There are no vaccines or effective antivirals available against
HRV, despite the fact that non-influenza related viral respiratory
infections, predominantly by HRV, lead to an economic loss of
USD 40 billion per year in the US alone and are among the top
reasons for prescription of antibiotics [7]. Earlier developments of
small compounds against HRV had targeted capsid or viral
protease functions, for example pleconaril or rupintrivir [8,9].
None of these antiviral molecules passed phase III clinical trials, or
was approved by the FDA for broad human applications.
We identified niclosamide (5-chloro-N-(2-chloro-4-nitrophenyl)-
2-hydroxybenzamide) as an inhibitor of HRV16 infection.
Niclosamide is an FDA approved anti-helmintic compound used
in humans since more than forty years [10]. It has been applied as
an agrochemical and in human therapy. It is well tolerated by rats
with an acute oral toxicity LD50 dose larger than 5 g/kg body
weight and only a marginal decrease in haemoglobin concentra-
tion and erythrocyte count occurred when male and female rats
were given niclosamide at 5 g/kg/day for four weeks [11].
Niclosamide was originally developed at Farbenfabriken Bayer based
on the observation that bithionol (2,29-sulfanediyl-bis(4,6-dichlor-
ophenol)) had potent antihelmintic activity. Later work on
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hydroxyl-biphenyls led to the discovery of niclofolan (5,59-
dichloro-2,29-dihydroxy-3,39-dinitrobiphenyl), which was modified
to niclosamide. Niclosamide was introduced into the market in
1960 under the trade name Bayluscide (Bayer 73), and has been used
over decades to treat gastrointestinal tapeworm infections, both in
humans and animals, [for an overview, see 12]. Niclosamide is
receiving renewed attention due to antiviral effects against severe
acute respiratory syndrome (SARS) virus [13], anti-anthrax toxin
properties [14], and anti-neoplastic activity [15]. In addition,
niclosamide is a potent inducer of LC3-positive autophagosomes
[16], an inhibitor of the Wnt/Frizzled pathway [17], a suppressor
of the autonomous notch-signalling pathway [18], and an inhibitor
of mTOR signalling [19]. In addition, it uncouples mitochondrial
oxidative phosphorylation [20], thus slowing down cell growth.
Results
Niclosamide is a broad range antiviral against pH
dependent viruses
In an image-based high-content infection screen of HeLa cells,
we identified niclosamide from a library of 1200 known bioactive
compounds as a potent, low micromolar inhibitor of HRV16
infection. We tested the efficacy of niclosamide to block
picornavirus infections using a panel of different enteroviruses,
comprising four HRVs and coxsackieviruses (CV). We found that
pH-dependent HRVs using the LDLR family (HRV1A, 2), the
ICAM1 tropic major group (HRV14, 16) and the genetic groups A
(HRV1A, 2 16) and B (HRV14) were sensitive to niclosamide at
IC50 (the concentration with 50% of the maximal inhibition) of
0.84 to 1.4 mM (Figure 1A, B and Figure S1A in Text S1). The
largely pH-independent coxsackie adenovirus receptor (CAR)-
tropic CVB3 and CVB4 [21], and the ICAM1-tropic CVA21
were broadly unaffected at 1 mM and had IC50 values of.50 mM,
3.88 mM and 6.63 mM, respectively. This is also reflected in the
therapeutic index (TI), reflecting the ratio of IC50 to CC50, the
latter being the concentration with half maximal toxicity. We
measured cellular energy levels using a resazurin fluorometric
assay to assess the toxicity of niclosamide. Toxicity was clearly
separated from antiviral efficacy against HRV1A, 2, 14, and 16 at
least 10-fold (see Figure 1A and Figure S1B in Text S1). The
toxicity profile closely matched the antiviral efficacy against herpes
simplex virus (HSV1), which had IC50 values exceeding 10 mM.
In contrast, niclosamide effectively inhibited influenza virus
(strain A/Puerto Rico/8/34/H1N1 depicted PR8) with an IC50 of
0.83 mM in human lung adenocarcinoma epithelial A549 cells, a
cell line fully permissive for influenza virus replication (Figure 1A).
Niclosamide was also an effective antiviral in non-transformed
cells, including WI-38 human embryonic diploid airway cells
infected with HRV1A (IC50 1.3 mM, Supplementary Figure S1C
in Text S1). However, it did not affect the inhibition profile when
viruses were pre-treated with niclosamide at up to 400 mM at 37uC
for 30 min, suggesting a non-virus target (Figure S2 in Text S1).
The cellular inhibition profile of niclosamide closely resembled
that of bafilomycin A1 (BafA1), which strongly inhibited HRV1A,
2, 14, 16 and mildly CVB4 but not CVB3 (Figure S3 in Text S1).
The profile was also similar to ammonium chloride addition
experiments (see Figure S7B in Text S1, and data not shown).
The high mutation rate and quasi-species nature of picornaviruses
facilitate the emergence and selection of drug-resistant escape
mutants, particularly if the restriction is directed against viral
factors [22]. We addressed this issue by blind propagation of
HRV1A and CVB3 in the presence of niclosamide at effective
concentrations ranging from 0.12–10 mM in approximately 24
HRV replication cycles. We did not observe a shift in sensitivity of
propagated HRV1A to niclosamide (Figure S4 in Text S1). It is
not known if this was due to low genetic complexity of the
inoculum, or lack of spontaneous mutations during passaging.
Collectively, these data show that pH-dependent infections are
more affected by niclosamide than pH-independent infections.
Niclosamide inhibits HRV entry
To assess at what stage of the viral life cycle niclosamide acted,
we added the compound before or post infection (pi) of HeLa cells
with HRV or CVB3 (Figure 2A, B, Figure S5A in Text S1). The
results show that addition of niclosamide before the genome
release was necessary for maximal inhibition of HRV infections,
with half maximal effects before or at 30 min pi, while CVB3
infection was unaffected. This suggested that niclosamide inhibited
an early step of infection, presumably virus entry. These results
were similar to time-course experiments with the entry inhibitor
pleconaril [21], which binds to HRV capsids, or with BafA1,
which neutralizes acidic endosomes by blocking the vacuolar
ATPase (see Figure S3 in Text S1).
To test if niclosamide was an irreversible inhibitor we pre-
treated cells with the compound for either 30 min or 18 h.
Washing the cells with drug-free medium completely abolished
the antiviral effect in both cases (Figure 2C and Figures S5B and
S5C in Text S1). This suggested that the mode of inhibition did
not involve high affinity drug targets or irreversible metabolic
changes in the cells even when exceeding 10-fold IC50 and long-
term incubation. To better define the inhibition mode of
niclosamide, we performed 19uC trapping experiments. At this
temperature, uptake of cargo into early endosomes is allowed, but
membrane maturation and sorting from these early compart-
ments are strongly slowed down [23]. HRV1A or HRV16 was
internalized at 19uC for 1, 2 or 3 h followed by treatment with
niclosamide at 37uC, or with drugs affecting capsid conversion.
Here, we used the term ‘capsid conversion’ to measure cellular
cues priming the virus for RNA release [5], for example virus-
receptor interactions or low endosomal pH. Capsid conversion
was measured by the sensitivity of HRV to pleconaril, which
binds to capsid and interferes with immediate early receptor
Author Summary
Current antiviral approaches are directed against specific
viral targets but are limited in their broad-spectrum
potential. Targeting host pathways, on the other hand
can have broad antiviral effects, albeit with possible side
effects. Here, we report the mode of antiviral action of a
small chemical compound, niclosamide. Niclosamide be-
longs to the salicylanilides, and has been FDA approved to
treat parasitic helminthic infestations in humans since
decades. In recent years, niclosamide was shown to have
anti-neoplastic and antiviral effects. We screened a library
of FDA-approved chemicals, and found that niclosamide is
an entry inhibitor for a number of pH-dependent
respiratory viruses, including influenza virus and human
rhinoviruses. Cell biological and biochemical analyses and
intracellular pH measurements showed that niclosamide
neutralizes acidic membrane-bounded compartments.
Niclosamide did not affect the vacuolar ATPase but acted
as a protonophore, both in vesicles isolated from cells, and
protein-free liposome assays. It blocked rhinovirus infec-
tions synergistically with the proton ATPase inhibitor
bafilomycin A1. Niclosamide targets endosomes by a
mode of action distinct from that of endosomal pH
neutralizing agents, such as chloroquine, which accumu-
lates in acidic endosomes.
A Proton Carrier with Broad Anti-viral Effects
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binding steps of ICAM1-tropic HRVs [24], and with endosomal
conversion of (v)LDLR- tropic HRVs, [unpublished data, and
25]. Our data show that the ICAM1-tropic HRV16 readily
bypassed the pleconaril block at 19uC (Figure 2D). The (v)LDLR-
tropic HRV1A, in contrast, remained at least partly pleconaril-
sensitive, indicating that it did not get past the 19uC step towards
an acidic compartment where the pH-dependent conversion step
occurs, as shown earlier for the (v)LDLR-tropic HRV2 [26]. As
expected, BafA1 inhibited the infection with both HRV1A and
HRV16, but not the pH-independent CVB3, when added after 1,
2 or 3 h at 19uC. Likewise, niclosamide blocked HRV1A and
HRV16 but not CVB3 when added after the 19uC block. We
conclude that niclosamide inhibited HRV1A and HRV16
infections after receptor binding and transport of virus to early
endosomes.
Niclosamide neutralizes pH and alters the distribution of
endosomes
The majority of niclosamide-sensitive viruses in this study,
namely, HRVs 1A, 2, 14, 16, and influenza virus PR8 require a
low-pH step for infectious entry [24,27,28]. We therefore tested if
niclosamide neutralized the low endosomal pH, as measured by
ratiometric imaging of acridine orange (AO) fluorescence [29]
(Figure 3A). AO accumulates in vesicular compartments and
emits red fluorescence, supposedly due to quenching in acidic
compartments. Upon treating cells with the lysosomotropic agent
NH4Cl, or the v-ATPase inhibitor BafA1 the emitted fluores-
cence of AO shifted from red to green, indicating de-quenching
upon endosomal pH neutralization. Ratiometric live cell mea-
surements showed that niclosamide increased the vesicular pH,
similar to NH4Cl or BafA1 (Figure 3G, and Figure S6A and B in
Figure 1. Niclosamide is a dose-dependent inhibitor of enterovirus and influenza virus infections. A). Niclosamide protects HeLa cells
from HRV1A, 2, 14 and 16 infections (n = 2), and A549 cells from Influenza A/PR8 (n = 2), while CVB3 (n = 2) and HSV1 (n = 6) infections were not
significantly affected, compared to the toxicity effects determined by resazurin measurements. Mean and SEM values are shown, percent relative to
DMSO-treated control cells (100%). The inset shows the IC50 concentrations for half maximal infection inhibitions and the therapeutic indices (TI),
defined as the ratio of IC50/CC50, where CC50 is the concentration at 50% cell viability. B). Sample images showing the effect of niclosamide on the
formation of dsRNA replication centers (mABJ2, Alexa488, green) at 7 h pi. Nuclei are stained with DAPI (blue). Bar = 100 mm.
doi:10.1371/journal.ppat.1002976.g001
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Text S1). These results were confirmed by lysotracker DND99
measurements, which showed a steep decline in fluorescence
upon treatment with micromolar concentrations of niclosamide,
or nanomolar concentrations of BafA1 (Figure 3B). This
indicated that niclosamide neutralized low pH endosomal
compartments.
Figure 2. Niclosamide inhibits virus entry post the 196C compartment. A). Time course of niclosamide (12.5 mM) addition and assessment of
HRV2 infection of HeLa cells, including DAPI staining for nuclei. B). Quantification of HRV2 and CVB3 infections from panel A with means of infection
values including SEM (n = 4). C). Impact of a drug washout on niclosamide efficacy against HRV1A, 16 and CVB3. Cells were pre-incubated with 10 mM
of compound for 30 min and either washed three times with PBS or drug. Mean values and SEM of n = 4 are shown relative to DMSO treated control
cells. D). Efficacy of BafA1 (50 nM), pleconaril (0.5 mg/ml) and niclosamide (5 mM) added to cells, which had been inoculated with HRV16, 1A or CVB3
for 1, 2 or 3 h at 19uC. Mean infection values and SEM of n = 3 are shown relative to DMSO controls.
doi:10.1371/journal.ppat.1002976.g002
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It is well established that endolysosomal acidification is largely
driven by v-ATPases by consumption of ATP, [reviewed in 30].
To test if niclosamide affected the v-ATPase activity, we isolated
bovine brain clathrin-coated vesicles (CCV), and measured the
hydrolysis of ATP by the production of inorganic phosphate (Pi).
While niclosamide had no effects on ATP consumption, the v-
ATPase inhibitors BafA1 or concanamycin A (Conc A) completely
blocked the production of Pi (Figure S6C in Text S1, for an
electron micrograph of isolated CCV, see Figure 3F). This
indicated that niclosamide did not inhibit the v-ATPase activity.
We next tested if the antiviral effect of niclosamide was due to
blocking of endosomal acidification. For this, we trapped HRV1A
in the 19uC compartment for 2 h in presence of niclosamide and
incubated the cells in medium with low pH for 1 h, followed by
normal infection medium without niclosamide for 6 h in presence
of pleconaril to inactivate non-converted particles. We found that
the addition of pH 5.5 or 6 medium reversed the inhibitory effect
of niclosamide on 19uC trapped viruses and promoted infection
(Figure 3C). The infection stimulation was more pronounced at
pH 5.5 than 6, possibly due to activation of virus penetration
through the plasma membrane. Similar results were obtained with
BafA1 treatment of 19uC trapped virus, where the inhibition was
reversed by pH 5.5 or 6, albeit pH 5.5 was more efficient than
pH 6 (data not shown). Notably, the treatment of cells with pH 5.5
buffer, which leads to acidification of the cytosol [31] did not
inhibit HRV1A infection. Together, the results indicate that
niclosamide affected a low pH-dependent step of the entry process
at or past the 19uC compartment.
Early endosomes are an important passageway for a variety of
viruses and have a mildly acidic pH of 6 to 6.5 [32]. Since we
observed that niclosamide inhibited viruses, which were strongly
pH dependent and also less pH dependent, we investigated if
niclosamide affected the phenotypes of early endosomes by
staining for early endosomal antigen 1 (EEA1). We found
morphologic alterations of EEA1 positive structures in niclosa-
mide-treated cells, specifically endosomal clustering in the
perinuclear area (Figure 3D, E). The perinuclear intensity of
LAMP1 (lysosomal associated membrane protein 1) positive
structures was less affected. Notably, BafA1 and to lesser extent
the lysosomotropic agents NH4Cl and chloroquine had compa-
rable phenotypic effects as niclosamide (Figure S6D and E in
Text S1). Similar results were also obtained with normal diploid
WI-38 cells indicating cell type independent effects (data not
shown). To test if niclosamide directly affected the pH within
endosomes, we measured the pH of isolated CCV by the AO
red fluorescence assay. Niclosamide, BafA1 and ConcA
neutralized the pH of CCV in a dose-dependent manner
(Figure 3F, G), notably with lower IC50 compared to cellular
assays, as seen frequently in cell free assays. Collectively, the
data indicate that niclosamide neutralized the pH of acidic
endosomes.
Antiviral efficacy of niclosamide co-tracks with
neutralization of endosomal pH
Niclosamide is a weak acid with an estimated pKa of 5.6 [33].
At pH 7.4, about 99% of the molecules are in the deprotonated
form. The octanol/water distribution coefficient (log P) of
niclosamide increases from pH 7.4 to 6 [33]. To test if there
was a correlation of antiviral activity and neutralization of
endosomal pH, we performed a structure-activity relationship
study with a library of sixteen niclosamide-related compounds,
each carrying different functional groups. As a positive control we
included niclosamide from two different sources, Prestwick and
SIGMA-Aldrich, and found that both reagents had a virtually
identical efficacy against HRV1A (Figure 4A). Four of the sixteen
niclosamide-related compounds had antiviral activity, comparable
to niclosamide (Figure 4A and 4B). TVB-1326, 1332 and 1334 all
contained features that stabilized their protonated forms, which
suggested that the hydroxyl group at R1 or the central amide NH
were the pH sensitive group. Condensation of the R1 hydroxyl
group with ethoxy-phenyl (TVB-1329) did not diminish the
antiviral efficacy compared to niclosamide, indicating that the R1
hydroxyl group alone was not essential. However, substituting the
R1 hydroxyl proton with an alkyl group and replacing the electro-
negative R4 Cl group with hydrogen (TVB-1328, 1331, 1333, and
1324) eliminated antiviral activity. The same was true when the
electron-withdrawing nitro group at R6 was replaced by less
electron-withdrawing groups (TVB-1338, 1335, 1336). The
importance of the electro-negative groups on the benzene rings
was confirmed by the reduced antiviral efficacy of TVB-1323,
1325, 1327, 1330 and 1337.
We confirmed the antiviral activity of TVB-1326, 1332, 1334
and 1329, but not of the control compound TVB-1338 against
the pH-dependent HRV1A, 2, 14, 16 and influenza virus PR8
and to a lesser extent CVB4 and CVA21 (Figure 4A, and Figure
S7A in Text S1). Similar to niclosamide, the antiviral active
compounds inhibited infection with HRV1A or HRV16 when
added during the early phase (30 min) but not when added post
entry at 120 min (Figure S7B in Text S1). CVB3 was only weakly
inhibited by the treatment with niclosamide or the compounds
TVB-1326, 1332, 1334 and 1329. The inhibition profiles were
comparable with the entry inhibitors BafA1 and NH4Cl,
although NH4Cl slightly affected the infection with CVB3. The
latter effect is likely due to pleiotropic effects of NH4Cl on cell
physiology. Furthermore, TVB-1326, 1329, 1332, 1334 but not
TVB-1338 readily neutralized acidic endosomes as determined
by the ratiometric AO assay or lysotracker fluorescence analyses
in HeLa cells (Figure 4C, D, and Figure S7C in Text S1).
Collectively, our studies indicated that the inhibition profile of
niclosamide and related compounds against acid-dependent
viruses closely matched with the pH neutralization profile of
the compounds.
Figure 3. Niclosamide neutralizes acidic endosomal pH and alters the distribution of endosomes. A). Ratiometric live cell imaging of
acridine orange (AO) green and red fluorescence. Nuclei were stained with Hoechst. B). The mean and SEM values of lysotracker fluorescence from
single cell measurements are plotted against niclosamide (mM) and BafA1 (nM) (n = 4) with an overview of lysotracker fluorescence from a 96-well
plate. C). Low extracellular pH bypasses niclosamide’s antiviral effect. Mean and SEM values of dsRNA-positive cells (n = 2). D). Influence of
niclosamide on the distribution of EEA1 (red) or LAMP1 (green) positive endosomes observed in single section confocal micrographs where nuclei
(blue) were stained with DAPI and filamentous actin (grey) with phalloidine. E). Quantification of the perinuclear intensity of EEA1 and LAMP1 positive
endosomes of cells from automated microscopy and single cell analyses relative to wild type levels (0) with means and SEM (n = 8). F). Electron
micrograph of a negatively stained cow brain CCV preparation. G). Percent normalized fluorescence of acridine orange (AO) (excitation 492 nm,
emission 540 nm) of control and inhibitor-treated CCV. The 100% signal is equivalent to the DMSO control treated vesicles.
doi:10.1371/journal.ppat.1002976.g003
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Niclosamide neutralizes protein-free acidic liposomes
and blocks infection in synergy with BafA1
To further explore the mode of action of niclosamide, we tested
the protonophoric ability of niclosamide in protein-free unilamel-
lar liposomes loaded with dextran-FITC. To quench FITC
fluorescence the liposomes were loaded at pH 5.15 in a manner
similar to endosomes loaded with dextran-FITC [34]. Upon short
incubation with niclosamide the FITC-fluorescence was rapidly
dequenched with half maximal efficacy at 14 mM (Figure 5A).
Fluorescence dequenching was similar to the protonophores DNP
(dinitrophenol) or CCCP (carbonylcyanid-m-chlorophenyl-hydra-
zone), validating the assay system. Notably, niclosamide did not
affect the integrity of the liposomes, indicated by laser scatter size
determination and electron microscopy of negative stained
liposomes, whereas the detergent Triton X-100 disintegrated the
liposomes. These data supplied direct evidence that niclosamide
acted as a proton carrier from acidic vesicular lumen to the pH
neutral cytosol (Figure 5B).
We next tested if combination treatments of cells with
niclosamide and BafA1 had additive or synergistic antiviral effects.
Pre-incubation of cells with serial dilutions of niclosamide
combined with BafA1 showed a strong ‘‘additive’’ inhibition of
HRV1A infection, as determined by single cell, high-content
infection assays (Figure 6A, B). At low concentrations of
niclosamide and BafA1 synergistic inhibition of infection was
found as determined with MacSynergy II (Figure S8 in Text S1).
Figure 4. Antiviral efficacy of niclosamide related compounds co-tracks with endo-lysosomal neutralization. A). Efficacy of niclosamide
and sixteen structurally related compounds against HRV1A infection of HeLa cells. Infection relative to DMSO treated controls (value 1) and means are
indicated (n = 3). Infections and analyses as shown in Figure 1. B). Chemical structures of the sixteen niclosamide-related compounds dubbed as TVB
compounds. C). Acridine orange (AO) assay for pH-neutralization of endosomal compartments of five TVB compounds with antiviral efficacy. The
perinuclear intensity of the red and green AO fluorescence was quantified. Mean and SEM values are shown (n= 2), representing more than 500 cells
per condition. D). Overview of green/red ratiometric fluorescence of cells treated with increasing concentrations of indicated compounds. False color
images correspond to the data in (c).
doi:10.1371/journal.ppat.1002976.g004
A Proton Carrier with Broad Anti-viral Effects
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The synergistic effects were in strong agreement with results from
full cycle assays where low concentrations of niclosamide (0.55 M)
or BafA1 (0.5 nM) alone decreased virus titers about five-fold, and
with the drug combination .300-fold (Figure 6C). Together, the
data indicate that host interference at the level of endosome
acidification by two distinct mechanisms synergistically blocks
virus entry and infection.
Discussion
To identify tools against human rhinoviruses, we screened a
library of FDA-approved chemical compounds [35]. Among the
top hits against HRV16 infection was niclosamide. Niclosamide is
well tolerated in humans. It can be orally used at 2 g per adult for
cestocidal treatment, leading to maximal serum concentrations of
0.25 to 6.0 mg/ml corresponding to 0.76–18.35 mM, which is well
within the anti-viral active concentration range and is non-toxic in
humans [36]. Niclosamide is a salicylamide compound, similar to
the thiazolide nitazoxanide, a pro-drug of the active compound
tizoxanide [37]. Nitazoxanide was shown to have a broad
spectrum of efficacy, albeit with an unknown mode of action. It
has anti-protozoan activity and efficacy against influenza virus,
hepatitis B, rotavirus, norovirus and is in phase II clinical trials for
chronic hepatitis in combination therapy with interferon [38–40].
It was also reported to inhibit the maturation of influenza virus
hemagglutinin, presumably in the Golgi apparatus and to disrupt
the membrane potential of Mycobacterium tuberculosis [41,42].
Nitazoxanide (pKa 5.8) also has antiviral efficacy against hepatitis
C virus (HCV), presumably by activating protein kinase R (PKR)
[PKR, 43]. However, using PKR-knock out mouse embryo
fibroblasts [44], we did not find a role of PKR in niclosamide
mediated block of infection with HRV1A (data not shown).
Nonetheless, niclosamide inhibits infection with the pH-dependent
viruses, HCV and SARS coronavirus [40,45,46], but the
mechanism of inhibition was unknown.
Here, we show that niclosamide inhibits infection with human
rhinoviruses and influenza virus by blocking the acidification of
the endolysosomal compartments. Niclosamide did not affect viral
uptake into cells, since it acted post conversion of HRV upon
receptor engagement and post the 19uC endocytic compartment.
Instead, niclosamide acted as a proton carrier and synergized with
the inhibitory effects of the v-ATPase inhibitor BafA1. This
process affects pH homeostasis of endosomes, which is tightly
maintained in normal cells, [reviewed in 47]. The mode of action
of niclosamide is different from the v-ATPase inhibitor BafA1, or
the lysosomotropic agents ammonium chloride (NH4Cl) or
chloroquine. The latter are trapped as cationic species in the
acidic organelles owing to their basic pKa, thereby elevating the
endosomal pH [48]. We speculate that the lower apparent toxicity
of niclosamide compared to v-ATPase inhibitors could be due to a
pH-tuned action based on the mildly acidic pKa of niclosamide.
This would be different from bafilomycin, which blocks the
rotation of v-ATPase subunits during proton flux independent of
the luminal pH [30]. Niclosamide did not affect the ATP
hydrolysis in purified CCV unlike BafA1 and required lower
micromolar concentrations for antiviral efficacy than lysosomo-
tropic agents, while NH4Cl is effective at low millimolar
concentrations [49,50]. Comparably, chloroquine has an IC90 of
20 mM for hepatitis C virus [51], or mono-dansyl-cadaverine has
an IC50 of 50–100 mM against dengue virus [52]. Unlike NH4Cl,
niclosamide does not apparently induce intracellular vacuoliza-
tion, suggesting that it does not accumulate in the aqueous lumen
of low pH compartments. This is supported by the observation
that the hydrophobicity index of niclosamide increases from
neutral to acidic pH as shown by experimental data [33].
Niclosamide acts differently than classical ionophores. Niger-
acin, for example, is a mitochondrial proton gradient uncoupler at
high concentrations of potassium ions (K+), and thereby catalyzes
the electro-neutral exchange of K+ for protons without affecting
the membrane potential [53]. The infection block by niclosamide
was reversed by addition of low pH medium, suggesting that the
endosomal pH rather than a pH gradient across the endosomal
membrane is crucial for HRV infection. This is distinct from
valinomycin, which disrupts the membrane potential by shuttling
Na+ and protons. It is also unlikely that niclosamide neutralizes the
endosomal pH by inhibition of counter-ion influx, since cation
efflux rather than anion influx accompanies endosomal acidifica-
tion at least in the mildly acidic range [54]. Further, the chemical
properties of niclosamide make it unlikely that it acts as an alkali
ionophore, such as monensin, which forms zwitter-ionic complex-
es with monovalent cations and transports them through
membranes [55]. Interestingly, niclosamide and its related
compounds not only inhibited the pH-dependent viruses HRV1A,
2, 14, and 16, but also, albeit moderately, the less pH-dependent
strain CVB4. These results are in good agreement with the
infection inhibition profile of EIPA (ethyl-isopropyl-amiloride), an
inhibitor of the sodium-proton exchanger regulating endosomal
pH [56]. For example, the niclosamide-sensitive CVB4 was as
sensitive to EIPA as HRV1A, 2, 14 or 16, while the niclosamide-
insensitive CVB3 was not affected by EIPA (data not shown). This
suggests that the ionic milieu of endosomes affects infections,
possibly by controlling membrane trafficking or homeostasis. This
was supported by the observation that niclosamide altered the
mildly acidic EEA1-positive early endosomal compartments. It is
possible that luminal pH controls the interaction of the membrane
trafficking regulator Arf6 with the c-subunit of the v-ATPase
complex, and the Arf GTP-exchange factor ARNO with the
membrane embedded a2-subunit, which anchors the ATPase
complex in the membrane and controls proton transport [57].
By showing that niclosamide induces the neutralization of
endosomal pH we offer an explanation for a variety of cell
biological effects attributed to this compound in the past.
Niclosamide has been safely used in humans since decades after
optimizations for the treatment of gastrointestinal parasites. It can
now also be tested in animal models for viral infection inhibition,
ideally by application via the inhaled route in order to obtain high
local concentrations for maximal efficacy. Modifications in its
chemical structure, e.g. generation of a pro-drug may prove useful
to advance the potential of physico-chemical interference for the
treatment of respiratory viral infections. The fact that niclosamide
Figure 5. Niclosamide neutralizes acidic liposomal pH similar as the protein gradient uncoupling agents DNP or CCCP. A). 200 nm
sized liposomes were prepared in presence of dextran-FITC (1 mM, 4.4 kDa) at pH 5.15 (top panel), which quenches FITC-fluorescence and
dequenched by the protonophoric action of niclosamide, 2,4-DNP (2,4-di-nitrophenol) or m-CCCP (m-chlorophenylhydrazone). The integrity of
liposomes upon treatment is shown as mean vesicle size (insert bar-graph). B). Model of the protonophore mode of action of niclosamide.
Niclosamide readily passes through biological membranes due to its lipophilic nature, as indicated by log P= 4.48 at pH 7.0 [33]. Niclosamide (pKa of
5.6) is protonated in the acidic compartment of endosomes, and thereby increases its lipophilicity (log P = 5.63 at pH 5.7). This may enhance its
partitioning into the lipid bilayer. In the pH-neutral cytosol a proton dissociates and the compound can interact again with membranes to repeat the
cycle. Note that the location of the proposed negative charge on niclosamide is not known.
doi:10.1371/journal.ppat.1002976.g005
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Figure 6. Synergistic antiviral efficacy of niclosamide and the v-ATPase inhibitor BafA1. Single round infections (a, b) with an overview
fluorescence microscopy montage of HeLa cells infected with HRV1A (green) in presence of increasing concentrations of niclosamide, BafA1 or
combinations thereof with cell nuclei stained with DAPI (blue). Bar is 100 mm. Viral titer production is indicated in panel (C).
doi:10.1371/journal.ppat.1002976.g006
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is a protonophore independent of protein targets with broad-
spectrum antiviral efficacy enforces the concept of host targeting
for antiviral therapies. It may spur the development of novel
directed protonophores tuned to particular cellular compartments.
Materials and Methods
Viruses and cells
Viruses and cells where essentially prepared as described [21].
HeLa cervical carcinoma cells strain Ohio (from L. Kaiser,
University Hospital Geneva, Switzerland), primary human
embryonic lung Wi-38 cells (American Type Culture Collection)
and human lung adenocarcinoma epithelial cells A549 (both from
ATCC) were cultured in Dulbecco’s Modified Eagle Medium
(DMEM) supplemented with L-glutamine, non essential amino
acids and 10% fetal bovine serum (all Sigma) at 37uC and 5%
CO2 in a humidified incubator and propagated sub-confluent
twice a week. In all experiments passage numbers were kept at a
maximum of 25 post thawing. For infection experiments in 96 well
plates (Matrix, Thermo Scientific) 14000 cells were split in 100 ml
the day before the experiment. HRV serotypes 1A and 16 were
from W.M. Lee (University of Wisconsin, Madison, WI, USA),
HRV 2 and 14 from L. Kaiser (University Hospital Geneva,
Switzerland) and CVB3, B4 and A21 from T. Hyypia¨ (University
of Turku, Finland). Influenza strain A (Puerto Rico/8/34/H1N1)
grown in MDCK cells was a kind gift from J. Pavlovic (University
of Zu¨rich, Switzerland). HSV-1 expressing GFP from the major
CMV promoter was a kind gift from C. Fraefel (University of
Zu¨rich). The genetic nature of HRV serotypes used was verified by
diagnostic sequencing [21].
Chemicals
BafA1 and ConcA were from Sigma-Aldrich & Enzo Life
Sciences (Switzerland). Niclosamide was obtained from two
sources, Prestwick (Illkirch, France) and Sigma. The batch from
Sigma was 100% pure by thin layer chromatography (Batch
058K1597, see supplier homepage for certificate of analysis). All
other TVB-compounds were supplied by 3-V Biosciences (Menlo
Park, CA, USA). The original screening library of FDA approved
compounds was from Prestwick.
Infection assays and automated high throughput
infection analysis
A single cell high-content, image based infection assay was
applied to measure infection in high throughput format [21].
Viruses were added to cells in infection medium containing BSA
(DMEM containing 25 mM HEPES if used outside of a CO2 cell
culture incubator, supplemented with L-glutamine, 30 mMMgCl2
and 0.2% BSA (Sigma) for CV and HRV), or in infection medium
containing trypsin-TPCK (DMEM supplemented with L-gluta-
mine and TPCK-trypsin 1 mg/ml (Sigma) for FLU/PR8) and
normal growth media for HSV. For all experiments, the
multiplicity of infection (moi) was chosen such that approximately
20–40% of the cells were infected at 7 h post infection (pi) (HRV
&CV), 8 h pi (FLU) or 18 h pi (HSV). Cells were fixed by adding
1/3 volume of a 16% para-formaldehyde solution, washed with
PBS, PBS/25 mM NH4Cl and PBS, permeabilized with 0.2%
Triton X-100 (Sigma), washed twice with PBS and blocked with
PBS/1% BSA (Fraction V, Sigma). Antibodies detecting viral
infection were used as follows: mAB J2 (English & Scientific
Consulting, Bt. Szira´k, Hungary) to detect HRV and CV
infections [21], and mAB HB65 detecting flu nucleoprotein (kind
gift from J. Pavlovic, University of Zu¨rich, Switzerland). For
secondary reagents we used Alexa-fluor labelled antibodies
(Invitrogen) together with 49,6-diamidino-2-phenylindole (DAPI)
to stain nuclei. Automated image acquisition was performed with
an ImageXpress Micro (Molecular Devices) equipped with a
CoolSNAP HQ 12bit grey-scale camera (Roper Scientific) and
106 SuperFluor Na 0.5, 206 SuperFluor Na 0.75, 406 Super-
FLuor Na 0.95 (Nikon) objectives. Routinely, 9–20 images per well
were acquired yielding an average of 5000–12000 cells analysed
per well and data point. Image overlays where made using
MetaXpress (Molecular Devices) and ImageJ (NIH Image, http://
rsbweb.nih.gov/nih-image/). Images were analyzed using a
custom written Matlab routine [21]. Dose response curve fittings
were obtained with PRISM software (version 5.01, GraphPad
Software Inc.) using standard Hill curve fittings. Infection indices
were represented as a function of log10 inhibitor concentrations to
determine the IC50 value for each drug, that is, the concentration
of the drug provoking a response half way between the top
response of the infection assay and the maximally inhibited
response using variable slope model, representing a four-
parameter dose-response curve.
Full cycle infectivity assays
To determine the effect of compounds on the production of
infectious virus, cells were treated as indicated and infected for
16 h. Progeny virus was recovered from the cells by three freeze/
thaw cycles and debris separated from supernatants by centrifu-
gation at 10006g for 3 min. Titers from supernatants were
determined with serial dilutions on HeLa-Ohio cells by staining
cells with crystal violet and calculation of TCID50 values according
to Spearman and Ka¨rber [58]. A 3 h infection sample served as
control for input virus carry-over.
Compound assays, 19uC endosomal trapping
experiments, pH rescue and capsid pre-incubation
experiments
Compounds were dissolved in dimethyl sulfoxid (DMSO, cell
culture grade, Sigma) and added to cells in dilutions indicated
with respective concentrations of solvent alone as controls. For
infection assays cells were pre-incubated with compound for
30 min or as indicated in infection medium. Virus was added to
the cells at 37uC for 7 h in presence or absence of compounds,
and cells were fixed and immune-stained for infection analyses.
For endosomal trapping, viruses were added to cells in infection
medium at 19uC and internalized for 1 to 3 h. The respective
compounds diluted in infection medium were added in an equal
volume 10 min before shifting the samples to 37uC for 7 h.
Infection was quantified by immune-staining for dsRNA. For
pH rescue, viruses were trapped at 19uC for 2 h in the presence
of compound. The medium was replaced by buffers containing
150 mM NaCl and different pH with or without niclosamide,
25 mM HEPES-NaOH pH 7.0, 25 mM morpholine-ethane-
sulfonic acid [MES] pH 6.5 or 6.0 or 25 mM sodium acetate
pH 5.5 [24]. Cells were infected at 37uC for 1 h, and infection
continued for another 6 h at 37uC in infection medium
containing 1 mg/ml pleconaril to inactivate non-converted
viruses. For capsid pre-incubation experiments with niclosamide
the indicated viruses were either incubated in a small volume
with niclosamide (5 ml) or in infection medium without
compound. After 30 min incubation at 37uC virus was added
to cells in 40 ml, followed either by addition of infection medium
or niclosamide (5 ml) to reach the respective concentrations from
the virus pre-treatment samples. After 7 h of infection cells were
fixed and immune-stained for infection analyses.
A Proton Carrier with Broad Anti-viral Effects
PLOS Pathogens | www.plospathogens.org 11 October 2012 | Volume 8 | Issue 10 | e1002976
Intracellular acridine orange and lysotracker pH assays
For intracellular pH measurements, about 20,000 HeLa-Ohio
cells were seeded into imaging compatible 96 well plates (Matrix,
Thermo Scientific), washed the next day with PBS and incubated
with compounds diluted in Hanks buffered salt solution (HBSS,
Invitrogen) at 37uC for 30 min. An equal volume solution of AO
(150 mg/ml, Life Technologies) and Hoechst 33342 (10 mg/ml,
Sigma) or lysotracker DND99 (0.2 mM from a 1 mM stock in
DMSO, Life Technologies) was added to the medium and
incubated at 37uC for 15 min. Cells were washed twice with
HBSS, and immediately imaged with ImageXpress Micro
(Molecular Devices) equipped with a CoolSNAP HQ 12 bit
grey-scale camera (Roper Scientific), a heating unit to keep the
imaging stage at 37uC and a 206 SuperFluor/Na 0.75 objective
(Nikon) and filter sets for AO (green: excitation 473/30 nm,
emission 520/35 nm; red: excitation 479/28 nm, emission 607/
36).
Quantification of acridine orange, lysotracker and
endosomal stainings
Quantification was performed using the open source image
analysis framework CellProfiler Version 2 (www.cellprofiler.org).
The raw fluorescence intensities were quantified in the perinuclear
area. Raw fluorescence intensities were from lysotracker DND99.
The ratios of green to red fluorescence (AO) or fluorescence
intensities of compartments stained for early endosomal antigen 1
(EEA1, rabbit polyclonal antibody, Novus Biologicals, Cat#
NB300-502) or LAMP1 (mouse H4A3 antibody, Santa Cruz
Biotechnology) were measured relative to untreated cells.
Acridine orange measurements in clathrin-coated
vesicles
CCV suspended in assay buffer (10 mM HEPES, pH7,
100 mM KCl, 1 mM EDTA) were incubated with 1 mM ATP,
2 mM AO (Molecular Probes). The ATPase reaction was initiated
by adding MgCl2 to 1 mM and fluorescence was determined at
492/540 nm in a plate reader (Tecan, Ma¨nnedorf, Switzerland) at
room temperature after 10 min. BafA1 and samples without
MgCl2 were used as controls.
v-ATPase inhibition assay
Cow brain CCV were prepared as described [59], diluted in
assay buffer (200 mM sucrose, 50 mM KCl, 10 mMHEPES pH7,
1 mM EDTA, 5 mM nigericin, 10 mg/ml oligomycin, 1 mM
vanadate) and incubated with the respective compounds at 4uC for
30 min. ATP (10 ml 2 mM ATP and 40 mM MgCl2) were added
and the samples incubated at 37uC for 15 min. Production of
inorganic phosphate (Pi) was measured with the Sensolyte MG
phosphate assay kit according to the manufacturers protocols
(AnaSpec).
Compound toxicity measured by resazurin fluorescence
Cell toxicity was assessed by the resazurin fluorometric method
[60]. In brief, sterile filtered resazurin (1 mg/ml stock solution in
PBS, Sigma) was stored protected from light at 4uC, and added to
cells to a final concentration of 0.16 mg/ml together with the
compounds of interest and incubated at 37uC in a 5% CO2
incubator as indicated. The conversion of resazurin to a
fluorescent product was measured using a plate reader (TECAN
Infinite 200) at excitation 550/9 nm and emission 590/20 nm
wavelength at constant gain over time at 37uC.
Liposome dextran-FITC de-quenching
Liposomes from soy phosphatidyl-choline were prepared in
100 mM acetate pH 5.15 containing 1 mM 4.4 kDa FITC-
dextran using standard extrusion protocols yielding vesicles of an
average size of 200 nm measured using a particle size analyzer
(Nicomp 370, Nicomp, Port Richey, FL, USA). Non-encapsulated
FITC-dextran was removed by size exclusion chromatography in
a G25 column (Pharmacia) followed by extensive dialysis against
100 mM acetate pH 5.15 in a Floatalyzer with 50 kDa cut-off
(Spectrumlabs). To measure fluorescence de-quenching FITC-
dextran containing liposomes were diluted in PBS at 20–60 mg/
ml, incubated with the respective compounds at room temperature
and analysed for fluorescence using a plate reader (TECAN Safire
II) with fluorescence TOP measurement settings at excitation of
483/10 nm and emission of 525/15 nm wavelength within
15 min. Control measurements of samples containing PBS, Triton
X-100 or the compounds alone were carried out to measure
background, maximal readout of the assay and auto-fluorescence
of compounds. The data were normalized to the PBS control and
background fluorescence was subtracted.
Synergy analyses
Cells were pre-treated with compounds alone or in combina-
tion, infected as indicated and analyzed using immune-staining
and automated microscopy as described above. MacSynergy II
[61] was used to calculate synergy interaction indices. Briefly,
theoretical additive interactions were calculated from the dose-
response curves of each individual drug. The calculated additive
surface was then subtracted from the experimental surface to
obtain a synergy surface representing percentage inhibition above
the calculated additive value. Any peak above the 0% plane
suggests synergy. Likewise, any peak below the 0% plane is
indicative of antagonism.
Supporting Information
Text S1 This file contains supporting figures S1 to S8
and references. Figure S1. Niclosamide is a dose-dependent
low micro-molar inhibitor of HRV in HeLa cells. Figure S2. Pre-
incubating HRV or CVB3 with niclosamide has no effects on
infectivity. Figure S3. Time course of bafilomycin A1 addition to
cells infected with HRV1A, 2, 14, 16 and the less pH dependent
CVB4, and the pH independent CVB3. Figure S4. No decrease
in antiviral efficacy of niclosamide upon HRV1A passage at low
drug concentrations. Figure S5. Niclosamide is an early and
reversible inhibitor of HRV1A, 2, 14 and 16 infections.Figure
S6. Niclosamide affects acidic compartments similar to BafA1 or
ammonium chloride but has no effect on the v-ATPase activity in
CCV preparations. Figure S7. Co-tracking of antiviral efficacy
with endosomal pH neutralization of niclosamide-related com-
pounds. Figure S8. Synergistic inhibition of HRV1A infection by
low concentrations of niclosamide and BafA1.
(PDF)
Acknowledgments
Peder Zipperlen, Sven Miller, Mohanram Sivaraja and Sandipan
Chatterjee (3V-Biosciences) are acknowledged for helping in preparing
the CCV and providing technical assistance with assay development in
Figure 3G and Figure S6C in Text S1, Karin Boucke (University of Zurich)
for electron microscopy, I-Hsuan Wang and Artur Yakimovich for help
with confocal microscopy and data analyses.
A Proton Carrier with Broad Anti-viral Effects
PLOS Pathogens | www.plospathogens.org 12 October 2012 | Volume 8 | Issue 10 | e1002976
Author Contributions
Conceived and designed the experiments: AJ EM UFG. Performed the
experiments: AJ. Analyzed the data: AJ UFG. Contributed reagents/
materials/analysis tools: RM SM RS. Wrote the paper: AJ UFG. AJ, EM
and UFG initiated the study. UFG coordinated the study.
References
1. Fleming A (1929) On the antibacterial action of cultures of a penicillium, with
special reference to their use in the isolation of B. influenzae. Br J Exp Path 10:
226–36.
2. Yazdanpanah Y (2009) Multidrug resistance: a clinical approach. Curr Opin
HIV AIDS 4: 499–506.
3. Le Gall O, Christian P, Fauquet CM, King AM, Knowles NJ, et al. (2008)
Picornavirales, a proposed order of positive-sense single-stranded RNA viruses
with a pseudo-T=3 virion architecture. Arch Virol 153: 715–727.
4. Hayden FG (2004) Rhinovirus and the lower respiratory tract. Rev Med Virol
14: 17–31.
5. Fuchs R, Blaas D (2010) Uncoating of human rhinoviruses. Rev Med Virol 20:
281–297.
6. Bochkov YA, Palmenberg AC, Lee WM, Rathe JA, Amineva SP, et al. (2011)
Molecular modeling, organ culture and reverse genetics for a newly identified
human rhinovirus C. Nat Med 17: 627–632.
7. Fendrick AM, Monto AS, Nightengale B, Sarnes M (2003) The economic
burden of non-influenza-related viral respiratory tract infection in the United
States. Arch Intern Med 163: 487–494.
8. Florea NR, Maglio D, Nicolau DP (2003) Pleconaril, a novel antipicornaviral
agent. Pharmacotherapy 23: 339–348.
9. Kaiser L, Crump CE, Hayden FG (2000) In vitro activity of pleconaril and
AG7088 against selected serotypes and clinical isolates of human rhinoviruses.
Antiviral Res 47: 215–220.
10. Ditzel J, Schwartz M (1967) Worm cure without tears. The effect of niclosamide
on taeniasis saginata in man. Acta Medica Scandinavica 182: 663–664.
11. anonymous (1988) Data sheet on pesticides No 63: niclosamide. World Health
Organisation (WHO): Food and Agriculture Organisation: International
Programme on Chemical Safety, Inchem. pp. WHO/VBC/DS/88.63.
12. Sharma S, Anand N (1997) Approaches to design and synthesis of antiparasitic
drugs. Pharmacochemistry library v 25. Amsterdam; New York: Elsevier. 511 p.
13. Wu CJ, Jan JT, Chen CM, Hsieh HP, Hwang DR, et al. (2004) Inhibition of
severe acute respiratory syndrome coronavirus replication by niclosamide.
Antimicrob Agents Chemother 48: 2693–2696.
14. Zhu PJ, Hobson JP, Southall N, Qiu C, Thomas CJ, et al. (2009) Quantitative
high-throughput screening identifies inhibitors of anthrax-induced cell death.
Bioorg Med Chem 17: 5139–5145.
15. Osada T, Chen M, Yang XY, Spasojevic I, Vandeusen JB, et al. (2011)
Antihelminth Compound Niclosamide Downregulates Wnt Signaling and Elicits
Antitumor Responses in Tumors with Activating APC Mutations. Cancer Res
71: 4172–4182.
16. Balgi AD, Fonseca BD, Donohue E, Tsang TC, Lajoie P, et al. (2009) Screen for
chemical modulators of autophagy reveals novel therapeutic inhibitors of
mTORC1 signaling. PLoS One 4: e7124.
17. Chen M, Wang J, Lu J, Bond MC, Ren XR, et al. (2009) The anti-helminthic
niclosamide inhibits Wnt/Frizzled1 signaling. Biochemistry 48: 10267–10274.
18. Wang AM, Ku HH, Liang YC, Chen YC, Hwu YM, et al. (2009) The
autonomous notch signal pathway is activated by baicalin and baicalein but is
suppressed by niclosamide in K562 cells. J Cell Biochem 106: 682–692.
19. Fonseca BD, Diering GH, Bidinosti MA, Dalal K, Alain T, et al. (2012)
Structure-Activity Analysis of Niclosamide Reveals Potential Role for Cytoplas-
mic pH in Control of Mammalian Target of Rapamycin Complex 1 (mTORC1)
Signaling. J Biol Chem 287: 17530–17545.
20. Weinbach EC, Garbus J (1969) Mechanism of action of reagents that uncouple
oxidative phosphorylation. Nature 221: 1016–1018.
21. Jurgeit A, Moese S, Roulin P, Dorsch A, Lotzerich M, et al. (2010) An RNA
replication-center assay for high content image-based quantifications of human
rhinovirus and coxsackievirus infections. Virol J 7: 264.
22. Thibaut HJ, De Palma AM, Neyts J (2012) Combating enterovirus replication:
state-of-the-art on antiviral research. Biochem Pharmacol 83: 185–192.
23. Dunn WA, Hubbard AL, Aronson NN, Jr. (1980) Low temperature selectively
inhibits fusion between pinocytic vesicles and lysosomes during heterophagy of
125I-asialofetuin by the perfused rat liver. J Biol Chem 255: 5971–5978.
24. Nurani G, Lindqvist B, Casasnovas JM (2003) Receptor priming of major group
human rhinoviruses for uncoating and entry at mild low-pH environments.
J Virol 77: 11985–11991.
25. Pevear DC, Tull TM, Seipel ME, Groarke JM (1999) Activity of pleconaril
against enteroviruses. Antimicrob Agents Chemother 43: 2109–2115.
26. Brabec M, Baravalle G, Blaas D, Fuchs R (2003) Conformational changes,
plasma membrane penetration, and infection by human rhinovirus type 2: role
of receptors and low pH. J Virol 77: 5370–5377.
27. Matlin KS, Reggio H, Helenius A, Simons K (1981) Infectious entry pathway of
influenza virus in a canine kidney cell line. J Cell Biol 91: 601–613.
28. Bayer N, Schober D, Prchla E, Murphy RF, Blaas D, et al. (1998) Effect of
bafilomycin A1 and nocodazole on endocytic transport in HeLa cells:
implications for viral uncoating and infection. J Virol 72: 9645–9655.
29. Palmgren MG (1991) Acridine-Orange as a Probe for Measuring Ph Gradients
across Membranes - Mechanism and Limitations. Anal Biochem 192: 316–321.
30. Forgac M (2007) Vacuolar ATPases: rotary proton pumps in physiology and
pathophysiology. Nat Rev Mol Cell Biol 8: 917–929.
31. Rogers J, Hesketh TR, Smith GA, Beaven MA, Metcalfe JC, et al. (1983)
Intracellular pH and free calcium changes in single cells using quene 1 and quin
2 probes and fluorescence microscopy. FEBS letters 161: 21–27.
32. Huotari J, Helenius A (2011) Endosome maturation. Embo J 30: 3481–3500.
33. Anonymous (2002) WHO SPECIFICATIONS AND EVALUATIONS FOR
PUBLIC HEALTH PESTICIDES: Niclosamide. WORLD HEALTH ORGA-
NIZATION GENEVA: 1–24.
34. Galloway CJ, Dean GE, Marsh M, Rudnick G, Mellman I (1983) Acidification
of macrophage and fibroblast endocytic vesicles in vitro. Proc Natl Acad Sci U S A
80: 3334–3338.
35. Wermuth CG (2004) Selective optimization of side activities: another way for
drug discovery. J Med Chem 47: 1303–1314.
36. Andrews P, Thyssen J, Lorke D (1982) The biology and toxicology of
molluscicides, Bayluscide. Pharmacol Ther 19: 245–295.
37. Korba BE, Montero AB, Farrar K, Gaye K, Mukerjee S, et al. (2008)
Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis
B virus and hepatitis C virus replication. Antiviral Res 77: 56–63.
38. Rossignol JF, Abu-Zekry M, Hussein A, Santoro MG (2006) Effect of
nitazoxanide for treatment of severe rotavirus diarrhoea: randomised double-
blind placebo-controlled trial. Lancet 368: 124–129.
39. Rossignol JF (2009) Thiazolides: a new class of antiviral drugs. Expert Opin
Drug Metab Toxicol 5: 667–674.
40. Stachulski AV, Pidathala C, Row EC, Sharma R, Berry NG, et al. (2011)
Thiazolides as Novel Antiviral Agents. 2. Inhibition of Hepatitis C Virus
Replication. J Med Chem.
41. Rossignol JF, La Frazia S, Chiappa L, Ciucci A, Santoro MG (2009)
Thiazolides, a new class of anti-influenza molecules targeting viral hemagglu-
tinin at the post-translational level. J Biol Chem 284: 29798–29808.
42. de Carvalho LP, Darby CM, Rhee KY, Nathan C (2011) Nitazoxanide Disrupts
Membrane Potential and Intrabacterial pH Homeostasis of Mycobacterium
tuberculosis. ACS Med Chem Lett 2: 849–854.
43. Elazar M, Liu M, McKenna SA, Liu P, Gehrig EA, et al. (2009) The anti-
hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation
factor 2alpha via protein kinase activated by double-stranded RNA activation.
Gastroenterology 137: 1827–1835.
44. Yang YL, Reis LF, Pavlovic J, Aguzzi A, Schafer R, et al. (1995) Deficient
signaling in mice devoid of double-stranded RNA-dependent protein kinase.
Embo J 14: 6095–6106.
45. Wen CC, Kuo YH, Jan JT, Liang PH, Wang SY, et al. (2007) Specific plant
terpenoids and lignoids possess potent antiviral activities against severe acute
respiratory syndrome coronavirus. J Med Chem 50: 4087–4095.
46. Zhang XW, Yap YL (2004) Old drugs as lead compounds for a new disease?
Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and
parasite drugs. Bioorg Med Chem 12: 2517–2521.
47. Casey JR, Grinstein S, Orlowski J (2010) Sensors and regulators of intracellular
pH. Nat Rev Mol Cell Biol 11: 50–61.
48. Ohkuma S, Poole B (1978) Fluorescence probe measurement of the
intralysosomal pH in living cells and the perturbation of pH by various agents.
Proc Natl Acad Sci U S A 75: 3327–3331.
49. Helenius A, Marsh M, White J (1982) Inhibition of Semliki Forest virus
penetration by lysosomotropic weak bases. J Gen Virol 58: 47–61.
50. Greber UF, Willetts M, Webster P, Helenius A (1993) Stepwise dismantling of
adenovirus 2 during entry into cells. Cell 75: 477–486.
51. Blanchard E, Belouzard S, Goueslain L, Wakita T, Dubuisson J, et al. (2006)
Hepatitis C virus entry depends on clathrin-mediated endocytosis. J Virol 80:
6964–6972.
52. Acosta EG, Castilla V, Damonte EB (2008) Functional entry of dengue virus into
Aedes albopictus mosquito cells is dependent on clathrin-mediated endocytosis.
J Gen Virol 89: 474–484.
53. Zoratti M, Favaron M, Pietrobon D, Petronilli V (1984) Nigericin-induced
transient changes in rat-liver mitochondria. Biochim Biophys Acta 767: 231–
239.
54. Steinberg BE, Huynh KK, Brodovitch A, Jabs S, Stauber T, et al. (2010) A
cation counterflux supports lysosomal acidification. J Cell Biol 189: 1171–86.
55. Pinkerton M, Steinrauf LK (1970) Molecular structure of monovalent metal
cation complexes of monensin. J Mol Biol 49: 533–546.
A Proton Carrier with Broad Anti-viral Effects
PLOS Pathogens | www.plospathogens.org 13 October 2012 | Volume 8 | Issue 10 | e1002976
56. Frelin C, Barbry P, Vigne P, Chassande O, Cragoe EJ, Jr., et al. (1988)
Amiloride and its analogs as tools to inhibit Na+ transport via the Na+ channel,
the Na+/H+ antiport and the Na+/Ca2+ exchanger. Biochimie 70: 1285–1290.
57. Hurtado-Lorenzo A, Skinner M, El Annan J, Futai M, Sun-Wada GH, et al.
(2006) V-ATPase interacts with ARNO and Arf6 in early endosomes and
regulates the protein degradative pathway. Nat Cell Biol 8: 124–136.
58. Spearman C (1908) The Method of ‘Right and Wrong Cases’ (Constant Stimuli)
without Gauss’ Formulae. Brit J Psychology 2: 227–442.
59. Crider BP, Xie XS (2003) Characterization of the functional coupling of bovine
brain vacuolar-type H(+)-translocating ATPase. Effect of divalent cations,
phospholipids, and subunit H (SFD). J Biol Chem 278: 44281–44288.
60. Czekanska EM (2011) Assessment of cell proliferation with resazurin-based
fluorescent dye. Methods Mol Biol 740: 27–32.
61. Prichard MN, Shipman C, Jr. (1990) A three-dimensional model to analyze
drug-drug interactions. Antiviral Res 14: 181–205.
A Proton Carrier with Broad Anti-viral Effects
PLOS Pathogens | www.plospathogens.org 14 October 2012 | Volume 8 | Issue 10 | e1002976
